Specialty Pharmacy

Researchers have discovered a natural protective mechanism that leads to the programmed death of potentially diseased cancer cells.

Shivani Patel, RPh, SVP, Clinical Operations and Technology, Asembia, discusses its reach in specialty pharmacy, and the company's growth.

In a lecture at the virtual Community Oncology Conference 2020, Christine Roussel discussed some clinical considerations for the use of medical cannabis in patients with cancer.

Research confirms earlier studies that found talazoparib improved patient-reported quality-of-life measures and had a tolerable safety profile.

The additional dosage is approved across all adult indications, including monotherapy and combination therapy, according to Merck.

Gregory Leighton, RPh, vice president of clinical solutions and patient access for Asembia, discusses how technology solutions can enhance collaborative care for specialty pharmacists.

A study recently investigated uterine serous carcinoma in order to more quickly identify those patients with an advanced form of the disease and find the appropriate treatment method for them.

There are a variety of interventions that can be used to improve survival after a patient reports cancer toxicity following treatment.

Individuals with the progressive condition often struggle to control their motor fluctuations.

Thom Cohn, chief strategy officer, Asembia, discusses recent developments in specialty pharmacy models.

An expert panel at the Community Oncology Conference 2020 discussed how COVID-19 is changing the future of community oncology.

Alexander Spira, MD, PhD, FACP, discussed how there are many types of malignancies when it comes to lung cancer, and we need to set this paradigm for our patients in the future.

The Alliance for Pharmacy Compounding created the tool to help address a need for drugs to treat patients with COVID-19.

According to the results of a nationwide survey conducted among clinical pharmacists, too many working hours is the major factor causing burnout, followed by inadequate management.

The current state of oncology is shaping challenges for the future specifically in the areas of telehealth, home infusions, and a surge of new patients that have not been to oncology clinics yet.

Experts discuss what their teams have learned throughout the COVID-19 pandemic, during the COA virtual conference.

Solving challenges of the current system is vital to spreading clinical trials into community clinics, which may be increasingly important.

Pharmacy adjudication systems vary among specialty pharmacies and many limitations still exist across most providers in the market.

New research has identified the binding site where drug compounds could activate a key braking mechanism against the runaway growth of many types of cancer.

Former NFL quarterback and Pro Football Hall of Fame member Jim Kelly announced as a keynote speaker for the 2020 NASP Annual Meeting & Expo.

Shivani Patel, RPh, SVP, Clinical Operations and Technology, Asembia discusses the use of digital tools to better connect industry leaders and health care professionals.

Sacituzumab govitecan-hziy is the first antibody-drug conjugates approved by the FDA specifically for relapsed or refractory metastatic triple-negative breast cancer (TNBC).

Implementation of adherence programs can be effective in improving outcomes for patients and reduce costs both at the patient and systemic level.

Using CRISPR technology, researchers conducted a study aimed at identifying genes that fuel leukemia growth, in order to find new vulnerabilities in chronic myeloid leukemia that can be targeted.

An analysis has shown that aspirin is associated not only with a significant reduction in the risk of developing several cancer types.

Cancer cells avoid an immune system attack after radiation by taking control of a cell signaling pathway that helps dying cells avoid triggering an immune response.

Patients with BRAF mutations administered treatment with encorafenib/binimetinib trended toward improved and longer responses than patients who received dabrafenib/trametinib.

In preliminary data from the trial evaluating dostarlimab, the results demonstrated that the clinical activity in patients with previously treated recurrent or advanced mismatch repair (MMR)-deficient endometrial cancer had an acceptable safety profile.

The new expanded approval was based on positive results from the phase 3 E1912 study.

Treatment of ovarian cancer with poly (ADP-ribose) polymerase (PARP) inhibitors has a high out-of-pocket cost for patients, with substantial variation among them, according to a study.